4D Molecular Therapeutics On Saturday, Announced Additional Interim Data From Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial In Patients with Wet AMD At ASRS 2023
Portfolio Pulse from Charles Gross
4D Molecular Therapeutics (NASDAQ:FDMT) announced additional positive interim clinical data from the Phase 1 Dose Exploration stage of the 4D-150 Phase 1/2 PRISM clinical trial for patients with wet age-related macular degeneration (wet AMD). The data showed a dose response in favor of the highest tested dose, with a 100% reduction in supplemental anti-VEGF injections and a clinically meaningful reduction in mean central subfield thickness at 36 weeks. The treatment remained well tolerated at all doses in all patients. Phase 2 Dose Expansion initial interim efficacy and safety data presentation is expected in H1 2024.
July 30, 2023 | 1:40 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
4D Molecular Therapeutics' positive interim data from the Phase 1/2 PRISM clinical trial for wet AMD could potentially boost investor confidence in the company's research and development capabilities.
The positive interim data from the clinical trial indicates that the company's research and development efforts are yielding promising results. This could potentially lead to increased investor confidence in the company's capabilities, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100